Dermatologic adverse events associated with afatinib: An oral ErbB family blocker Journal Article
| Authors: | Lacouture, M. E.; Schadendorf, D.; Chu, C. Y.; Uttenreuther-Fischer, M.; Stammberger, U.; O'Brien, D.; Hauschild, A. |
| Article Title: | Dermatologic adverse events associated with afatinib: An oral ErbB family blocker |
| Abstract: | Dermatologic adverse events (AEs) are frequently observed in patients receiving EGF receptor (EGFR; also known as ErbB1) tyrosine kinase inhibitor therapy. The impact of these AEs goes beyond cosmesis to the discomfort from itching, pain and secondary infections, all of which may significantly impact on patient well-being, adherence and clinical outcomes. Afatinib is a potent, irreversible, oral, ErbB family blocker, inhibiting EGFR (ErbB1), HER2 (ErbB2) and ErbB4 receptor kinases. It also inhibits transphosphorylation of ErbB3. Similar to EGFR inhibitors, dermatologic AEs have been frequently observed in patients treated with afatinib. Papulopustular (acneiform) rash, pruritus, xerosis, paronychia and alopecia will require patient education and proactive treatment interventions. This article summarizes current data on the dermatologic AEs associated with afatinib treatment across the clinical trial program, and provides strategies for their effective management. © 2013 2013 Expert Reviews Ltd. |
| Keywords: | antibiotic agent; overall survival; drug tolerability; review; erlotinib; placebo; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; monotherapy; side effect; solid tumor; capecitabine; paclitaxel; unindexed drug; quality of life; drug eruption; pain; breast cancer; lung non small cell cancer; mucosa inflammation; epidermal growth factor receptor; epidermal growth factor receptor 2; patient education; steroid; drug dose escalation; pruritus; maculopapular rash; skin exfoliation; antiinfective agent; lung adenocarcinoma; drug response; acne; gefitinib; erythema; hair; skin disease; drug substitution; epidermal growth factor receptor 3; doxycycline; tacrolimus; breast metastasis; hand foot syndrome; dry skin; metronidazole; minocycline; alopecia; lapatinib; radiation dermatitis; epidermal growth factor receptor kinase inhibitor; pyoderma gangrenosum; antihistaminic agent; papular rash; paronychia; skin fissure; xerosis; erythromycin; epidermal growth factor receptor 4; acne-like rash; head and neck squamous cell carcinoma; hypertrichosis; molecularly targeted therapy; pustule; clindamycin; silver nitrate; papulopustular rash; desonide; triamcinolone acetonide; alclometasone; egf receptor; vesicular rash; skin rash; 4 aminobutyric acid receptor stimulating agent; afatinib; dermatologic adverse event; fluticasone propionate; oxytetracycline; bullous dermatitis; erythroderma; macular rash; secondary infection |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 13 |
| Issue: | 6 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2013-06-01 |
| Start Page: | 721 |
| End Page: | 728 |
| Language: | English |
| DOI: | 10.1586/era.13.30 |
| PROVIDER: | scopus |
| PUBMED: | 23506519 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 August 2013" - "CODEN: ERATB" - "Source: Scopus" |
